more

Celcuity (CELC)

(Real Time Quote from BATS)

$17.00 USD

-0.24 (-1.39%)

Updated Apr 24, 2024 02:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Celcuity (CELC) Might Surprise This Earnings Season

by Zacks Equity Research Published on March 21,2024

Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CELCNegative Net Change

Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet

by Zacks Equity Research Published on June 15,2022

The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CELCNegative Net Change

Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on May 30,2022

The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CELCNegative Net Change

Celcuity, Inc. (CELC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research Published on April 23,2021

Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

CELCNegative Net Change

Celcuity's (CELC) Shares March Higher, Can It Continue?

by Zacks Equity Research Published on April 15,2021

As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).

CELCNegative Net Change

medical

Company News for Apr 12, 2021

by Zacks Equity Research Published on April 12,2021

Companies in the news are: AFMD, FUBO, GENE, CELC

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

by Zacks Equity Research Published on April 12,2021

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

biotechs

Company News for Mar 18, 2021

by Zacks Equity Research Published on March 18,2021

Companies in the news are: LE, SMTC, CRAWA, CELC

The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private

by Zacks Equity Research Published on December 12,2019

The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private

airlines

4 Small Cap Stocks to Get Rid of Before Entering 2020

by Nikita Kataruka Published on December 11,2019

While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.

All You Need to Know About Celcuity, Inc. (CELC) Rating Upgrade to Buy

by Zacks Equity Research Published on November 01,2019

Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CELCNegative Net Change

Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%

by Zacks Equity Research Published on September 24,2019

Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

CELCNegative Net Change

medical

Ultragenyx to Submit sBLA for Label Expansion of Crysvita

by Zacks Equity Research Published on September 11,2019

Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.

biotechs

Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy

by Zacks Equity Research Published on September 10,2019

Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.

biotechs

Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review

by Zacks Equity Research Published on September 10,2019

Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.

pharmaceuticals

Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

by Zacks Equity Research Published on August 19,2019

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

biotechs

Celcuity, Inc. (CELC) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research Published on August 19,2019

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CELCNegative Net Change

What Makes Celcuity, Inc. (CELC) a New Strong Buy Stock

by Zacks Equity Research Published on June 27,2019

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CELCNegative Net Change

Celcuity, Inc. (CELC) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research Published on May 13,2019

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.